Treatment Of Pityriasis Versicolor Research Articles

Treatment of pityriasis versicolor with a single dose of fluconazole.

Twenty-four patients with extensive or recurrent pityriasis versicolor were treated with a single oral dose of 400 mg of fluconazole. Twenty-three patients returned for follow up. Seventeen or 74%, were free of lesions 3 weeks after treatment and no recurrences were seen 6 weeks after treatment. The majority of the patients found the treatment effective, safe and convenient.

Ketoconazole in the Treatment of Pityriasis Versicolor: International Review of Clinical Trials

Multiple open and double-blind studies have confirmed the efficacy of ketoconazole in the treatment of pityriasis versicolor. Single-dose (400 mg) or short-course (200 mg/d for five days) therapy may be highly effective for selected patients with pityriasis versicolor. Toxicity seems to be minimal at this dosage.

Itraconazol no tratamento da pitiríase versicolor: comparação entre 5 e 7 dias de tratamento

The authors present the results obtained in the treatment of pityriasis versicolor with Itraconazole, comparing two schemes of treatment, in an open trial: 200 mg daily, for 5 and 7 days. The clinical diagnosis was confirmed by Wood's light and mycologically, by direct examination. The patients were controlled 21 and 35 days after beginning the treatment. The evaluation of the results showed that both schemes were effective. At the second control, there was clinical and mycologic cure in 90% of the patients from the 5-day group and in 95% of the patients from the 7-day group. The tolerance was good: 2 patients from the 7-day group and 1 patient from the 5-day group showed side-effects. Since there was no significant difference between the two schemes of treatment, the authors recommend the shortest one, that is, 200 mg daily for 5 days.

Itraconazole in the treatment of superficial mycoses-a double-blind study vs. placebo

Ninety-four patients with dermatophytosis and 16 patients with pityriasis versicolor were assigned under double-blind conditions to oral itraconazole (100 mg once daily) or placebo. The medication consisted of two capsules, each containing 50 mg of active substance, or placebo and was given for 15 or 30 days in patients with dermatophytosis and for 15 days in patients with pityriasis versicolor. Patients with pityriasis versicolor who had not responded at the end of the double-blind period were treated on an open basis with itraconazole (100 mg once daily) for 15 days. In the treatment of dermatophyte infections for 30 days, both clinical response and mycological cure were significantly superior in the itraconazole group compared with placebo. Oral administration of itraconazole (100 mg once daily) was also highly efficacious in the treatment of pityriasis versicolor. None of the placebo patients was clinically or mycologically cured at the end of the double-blind phase compared to seven out of eight itraconazole patients. All placebo patients who entered the open phase responded to itraconazole treatment. Three itraconazole-treated patients and nine placebo-treated patients reported side-effects.

Itraconazole: 200mg for 5 days appears effective and the most convenient regimen in the treatment of pityriasis versicolor

Itraconazole: 200mg for 5 days appears effective and the most convenient regimen in the treatment of pityriasis versicolor

Itraconazole, a new orally active antifungal, in the treatment of pityriasis versicolor.

Itraconazole, a new orally active triazole antifungal, has been tested in patients with pityriasis versicolor. A comparison of different dose schedules was carried out in 73 patients. A regime of 100 mg itraconazole daily for 15 days gave a 100% response rate; 200 mg daily for 5 days gave an 80% response rate. Two patients, who had received 50 mg itraconazole for 14 days, relapsed within 2 months of finishing treatment. Only two patients reported minor side-effects.

Tioconazole in the Treatment of Fungal Infections of the Skin

In 32 studies involving 1,304 patients tioconazole 1% dermal cream has been shown to be effective and safe in the treatment of a wide variety of superficial fungal infections of the skin and erythrasma. Tioconazole cream is more effective than miconazole nitrate 2% cream in the treatment of pityriasis versicolor and in infections with Trichophyton rubrum and Trichophyton mentagrophytes which cause 70% of dermatophyte infections in man. Data from comparisons with econazole and clotrimazole are too few to allow conclusions to be drawn on relative efficacy. All the creams were easy to apply and there were no serious adverse reactions, local or systemic.

Treatment of pityriasis versicolor with ketoconazole.

Eighty-two patients with pityriasis versicolor were treated orally with ketoconazole in tablet form (200 mg). The tablets were taken at least 90 min before a meal, and patients who received only one tablet daily were told to refrain from bathing except immediately before ingestion of the drug and only once a day. Dosage of ketoconazole varied from a single dose of 400 mg to 200--400 mg per day for four weeks. Seventy-seven patients reported no adverse effects. There were reports from others of headache, gastralgia, nausea, dyspnea, dizziness, or tinnitus. In most affected patients, these symptoms stopped with the first meal eaten after initiation of treatment. Follow-up examinations were performed at different intervals. The maximal therapeutic effect of ketoconazole was seen three to six weeks after initiation of therapy. Seventy-eight patients were considered cured; one had received only one tablet. Only hypopigmented macules remained. Examination of these areas with a Wood lamp revealed no fluorescence, and scrapings examined with the light microscope did not contain Malassezia furfur. These results indicate that ketoconazole is effective in the treatment of pityriasis versicolor, but the problem of protecting susceptible persons from infection and reinfection remains.

Double-Blind Trial of 1% Clotrimazole Cream and Whitfield Ointment in the Treatment of Pityriasis Versicolor

To the Editor.— We have recently completed a double-blind trial of clotrimazole (Lotrimin, [Canesten (Br)]) compared with benzoic and salicylic acid (Whitfield) ointment in the treatment of pityriasis versicolor. Clotrimazole is a tritylimidazole derivative with a wide spectrum of antifungal activity including in vitro fungistatic activity against Malassezia furfur.1One percent clotrimazole cream is as effective as Whitfield ointment and more acceptable to the patient. Culture of Malassezia furfur showed a constant and persistent sensitivity to clotrimazole, suggesting its suitability for treatment of relapse. Clinical assessment of hypopigmented lesions at follow-up is not as reliable a test of cure as microscopy of scrapings. Method.— During a two-year period, all patients seen in the skin department and found to be positive for Malassezia furfur on microscopy of skin scrapings were included in the trial. The patients were allotted at random to treatment with Whitfield ointment (3% salicylic acid and

Double-blind trial of 1% clotrimazole cream and Whitfield ointment in the treatment of pityriasis versicolor

Double-blind trial of 1% clotrimazole cream and Whitfield ointment in the treatment of pityriasis versicolor

Terbinafin 1% Cream and Ketoconazole 2% Cream in the Treatment of Pityriasis Versicolor: A randomized comparative clinical trial.

Objective: To make a comparison between terbinafine 1% cream and ketoconazole 2% cream in the treatment of pityriasis versicolor. Methods: This randomized single blind study included 110 patients with clinical diagnosis of pityriasis versicolor and positive mycological test for Malassezia furfur. The patients were randomly assigned to two groups. Group 1 used terbinafine cream and group 2 applied ketoconazole cream on the skin lesions for two weeks. Each group consisted of 55 patients. Clinical and mycological examinations were performed at baseline, at the end of the 2nd, 4th and 8th week of starting the treatment regimens. Results: At the end of the 2nd week we achieved cure rates of 72% and 64.3% for group 1 and group 2 respectively. At the end of the 4th week the respective cure rates for group 1 and group 2 were 81.2% and 69%, and at the end of the 8th week 70.8% of the patients in group 1 and 61.9% of the patients in group 2 were cured. Conclusion: The results of this study showed no significant statistical differences between the two groups in regard to cure and recurrence rates. But the numbers of cured patients were higher and recurrent cases were lower in group 1.